Hemab Therapeutics

Focus: Hemab Therapeutics is a Denmark-based biotech focused on bleeding disorder treatments, particularly rare hematologic conditions like Von Willebrand Disease and Glanzmann Thrombasthenia. With 5,000+ employees, the company operates at Series C+ stage with an established clinical development footprint.

Hematology

Profile data last refreshed 21h ago · AI intelligence enriched 2w ago

Funding Stage

SERIES C +

Employees

5000+

Open Jobs

Should You Work at Hemab Therapeutics?

AI assessment

Best fit for specialists seeking deep domain expertise in rare bleeding disorders with moderate growth prospects; poor fit for generalists seeking rapid expansion or near-term commercial upside.

Why Work Here

Focused therapeutic area (hematology/bleeding disorders) offers deep specialization and niche expertise that commands premium market positioning

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Early-stage

8 total

LOE Risk

Protected

No near-term cliffs

Hiring

8 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Comparison of blood samples between the two groups

Leiomyoma, Uterine

N/A

Clinical Trials (1)

NCT05607602Are Uterine Fibroids Pro-thrombotic?

N/A

Help build intelligence for Hemab Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Series C+ funding stage with 5,000+ employees indicates stability beyond early-stage risk while maintaining growth trajectory

Active clinical pipeline with Phase 1/2 programs (HMB-001, HMB-002, Sutacimig) provides clear catalyst visibility for career advancement and learning

Watch Out For

Only 6 active job openings and hiring concentrated in non-core functions (Clinical Ops, CMC, Finance, Medical Writing) suggests limited headcount expansion and bottleneck for career mobility
Pipeline remains early-stage (no Phase 3 programs) with uncertain probability of success; rare disease focus limits market size and revenue upside compared to larger biotech peers

Generated by Claude from Hemab Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Online Survey

Von Willebrand Diseases

N/A

Clinical Trials (1)

NCT06064643The Lived Experience of People With Von Willebrand Disease

N/A

Clinical outcomes of patients with VWD, Type 1

Von Willebrand Disease (VWD)

N/A

Clinical Trials (1)

NCT06610201A Study of Bleeding and Treatment in Participants With Von Willebrand Disease

N/A

ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

Hematologic Disorder

N/A

survey and interview

Glanzmann Thrombasthenia

N/A

Clinical Trials (1)

NCT05315232The Experiences of People Who Live With Glanzmanns Thrombasthenia.

N/A

HMB-001

Glanzmann Thrombasthenia

PHASE_1_2

Clinical Trials (1)

NCT06211634A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia

Phase 1/2

HMB-002

Von Willebrand Disease (VWD)

PHASE_1_2

Clinical Trials (1)

NCT06754852A Study Assessing HMB-002 in Participants With Von Willebrand Disease

Phase 1/2

Sutacimig

Congenital Factor VII Deficiency

PHASE_2

Clinical Trials (1)

NCT07347249A Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII Deficiency

Phase 2

Interview Prep Quick Facts

Portfolio: 7 clinical trials

Top TAs: Cardiovascular, Women's Health

Publications: 3 in PubMed

Open Roles: 8 active jobs

Therapeutic Area Focus

Cardiovascular

1 pipeline

Women's Health

1 pipeline

Marketed

Pipeline

Research Publications(3)

Recent peer-reviewed publications with author affiliations at this company

HMB-002: A Monovalent Antibody that Elevates Circulating VWF and FVIII Levels for Treatment of Von Willebrand Disease.

Blood advances

2026

PMID:41569789

A bispecific antibody approach for the potential prophylactic treatment of inherited bleeding disorders.

Nature cardiovascular research

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Hemab Therapeutics

Should You Work at Hemab Therapeutics?

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Open Jobs (8)

Vendor and Project Manager

Accountant

Senior Director of Clinical Operations – HMB-002 program

Senior Director of Clinical Operations – sutacimig program

Senior Director, Quality Assurance GCP

Director, Regulatory Affairs

Senior Clinical Trial Associate

Director, Clinical pharmacology

Research Publications(3)